Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-Warfarin is the S-enantiomer of warfarin, a vitamin K antagonist used as an anticoagulant medication. It is the more potent enantiomer in the racemic warfarin mixture, being 2.7 to 3.8 times more potent than the R-enantiomer. (S)-Warfarin works by inhibiting vitamin K epoxide reductase, preventing the recycling of vitamin K and thus interfering with the synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X) and regulatory proteins C and S. This S-enantiomer is primarily metabolized by the CYP2C9 enzyme in the liver, making drug interactions affecting this pathway particularly significant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-warfarin.